Developing Optimal Strategies for Reducing Morbidity in Patients with Non-Cystic Fibrosis Bronchiectasis is organized by Healio.
Release Date: July 15, 2023
Expiration Date: July 14, 2024
Activity Description
This case-based morbidity and mortality review (MMR) assesses the negative implications of suboptimal therapeutic management for patients with non-cystic fibrosis bronchiectasis. Cases and expert discussions focus on ensuring a prompt and accurate diagnosis of bronchiectasis, understanding the benefits of high-frequency chest wall oscillation (HFCWO), and identifying patients who can benefit from HFCWO.
Learning Objective
Upon completion of this activity, learners will be able to:
• Describe the clinical and economic burden of non-cystic fibrosis bronchiectasis
• Compare the benefits and drawbacks of various therapies for impaired airway clearance
• Identify patients who would be candidates for high-frequency chest wall oscillation (HFCWO) as part of an airway clearance therapy (ACT) treatment regimen